Tom- remacemide is made by Astrazeneca. It is one of the 2 substances being used in the CARE-HD trial sponsored by the Huntingtons Study Group. The study has gone into open label, meaning that the drug is available to all who were subjects in the study.The data from the study will have to be analyzed, which will take some time, before we know if it has been helpful.